Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Payables (2017 - 2025)

KalVista Pharmaceuticals' Payables history spans 11 years, with the latest figure at $4.9 million for Q2 2025.

  • On a quarterly basis, Payables fell 46.38% to $4.9 million in Q2 2025 year-over-year; TTM through Apr 2025 was $4.9 million, a 46.38% decrease, with the full-year FY2025 number at $4.9 million, down 46.38% from a year prior.
  • Payables hit $4.9 million in Q2 2025 for KalVista Pharmaceuticals, down from $5.7 million in the prior quarter.
  • Over the last five years, Payables for KALV hit a ceiling of $10.8 million in Q3 2024 and a floor of $641000.0 in Q1 2021.
  • Historically, Payables has averaged $5.1 million across 4 years, with a median of $4.9 million in 2023.
  • Biggest five-year swings in Payables: crashed 78.28% in 2021 and later surged 113.28% in 2024.
  • Tracing KALV's Payables over 4 years: stood at $2.0 million in 2021, then soared by 147.15% to $4.9 million in 2023, then increased by 16.95% to $5.7 million in 2024, then fell by 14.72% to $4.9 million in 2025.
  • Business Quant data shows Payables for KALV at $4.9 million in Q2 2025, $5.7 million in Q4 2024, and $5.2 million in Q4 2024.